The spin-off listing of Sisram Medical Ltd (“Sisram Med” or “the Company”, 1696.HK) , a holding subsidiary of Fosun Pharma (2196.HK), on the Main Board of the Stock Exchange of Hong Kong was successfully completed on September 19. The offer price was HK$ 8.88 per Share. The offer size is about HKD 976.80 million pre-over allotment and about HKD 995.94 million post over allotment. Sisram Med is the first Israeli company, the first and the only energy-based medical aesthetic treatment systems company listed in Hong Kong, representing a remarkable milestone for the Israeli companies and the energy-based medical aesthetic treatment system industry. CICC acted as the Joint Sponsor, Joint Global Coordinator, Joint Bookrunner, Joint Lead Manager, Sole Stabilizing Manager and Settlement Agent of this IPO.

After almost 20 years focusing on the research and development, production and sale of energy-based medical aesthetic treatment systems, the company has become a leading global provider in this field. Products of the company are sold in approximately 80 countries and jurisdictions and are highly recommended worldwide. Sisram Med has also been the largest provider of energy-based medical aesthetic treatment systems in the PRC market and ranked fifth in the medical aesthetic treatment system market globally, in terms of revenue in 2016. With the strongest profitability in comparison with the top four US listed competitors, Sisram Med is well deserved to be recognized as the industry leader.

With a deep understanding of the energy-based medical aesthetic treatment system industry and customer’s preference, CICC helped Sisram Med to discover a full-fledged investment highlights for its debut in the capital market. International placing was moderately over-subscribed and HKPO was approximately 17.58x oversubscribed of the Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, achieving the ultimate success of listing on the Main Board of the Stock Exchange of Hong Kong.

As the Joint Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager of this IPO, CICC fully coordinated the entire process, undertook the lead role in formulating equity story, drafting of prospectus, obtaining CSRC and HKEx approval, obtaining the approval from HKEx to include Israel as one of the “acceptable jurisdictions of listing”, introducing cornerstone investors as well as other key work streams, ensuring the success of the Global Offering.

With its rich experience in project execution and strong edge on comprehensive service, CICC has won high praise and extensive recognition from the client in this deal. Assisting Sisram Med in becoming the first Israeli company listed on the main board of Hong Kong Stock Exchange reflects that CICC actively responds to “the Belt and Road Initiative” and are committed to playing an important role to facilitate the cross-border capital cooperation as a bridge. As a leading investment bank with “China Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and business development.